Inhalon Biopharma Email Format

Biotechnology ResearchNorth Carolina, United States2-10 Employees

Inhalon Biopharma is a clinical-stage biotechnology company based in Durham, North Carolina, focused on developing an inhaled immunotherapy platform to treat acute respiratory infections such as RSV, influenza, MPV, PIV, adenovirus, SARS, and MERS. The approach centers on muco-trapping antibodies designed to bind pathogens in lung mucus, crosslinking them to mucins so they cannot infect cells and can be cleared from the airways through normal mucus clearance. This mechanism aims to reduce local infection and facilitate rapid elimination of pathogens from the lungs, addressing a market where there are currently no approved treatments for a broad range of ARIs that can lead to hospitalization or serious health outcomes. The company operates in the biotechnology research industry and has announced recent scientific publications and a human challenge trial for RSV, reflecting its ongoing work to advance its inhaled antibody platform.

Get verified Inhalon Biopharma emails free

Company overview Employee directory